Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450521 · ClinicalTrials.gov registry record · Phase 1
Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males
A Phase 1 study of Healthy Adult Male, sponsored by Mediar Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07450521 is a Phase 1 study of Healthy Adult Male that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07450521, a Phase 1 study of Healthy Adult Male, is actively recruiting participants, sponsored by Mediar Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-463
Study Locations (1)
Utah
- Icon Slc Cru - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07450521
The ClinicalTrials.gov registry entry for NCT07450521 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mediar Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adult Male appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07450521 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT07450521 about?
NCT07450521 is a clinical study titled "Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males". A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
What is the current status of trial NCT07450521?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-02-18. Estimated completion is 2026-03.
What conditions does trial NCT07450521 study?
This clinical trial studies the following conditions: Healthy Adult Male.
What interventions are being tested in trial NCT07450521?
The interventions under investigation include: Placebo (OTHER), MTX-463 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07450521?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07450521 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.